OraSure Technologies (OSUR) Aperçu de l'action
OraSure Technologies, Inc. et ses filiales développent, fabriquent, commercialisent, vendent et distribuent des produits de diagnostic et des dispositifs de prélèvement d'échantillons aux États-Unis, en Europe, en Afrique et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Analyse des risques
Aucun risque n'a été détecté pour OSUR à partir de nos contrôles de risques.
OSUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OraSure Technologies, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$3.61 |
| Plus haut sur 52 semaines | US$3.82 |
| Plus bas sur 52 semaines | US$2.08 |
| Bêta | 0.89 |
| Variation sur 1 mois | 15.71% |
| Variation sur 3 mois | 31.27% |
| Variation sur 1 an | 43.25% |
| Variation sur 3 ans | -26.02% |
| Variation sur 5 ans | -62.43% |
| Évolution depuis l'introduction en bourse | -34.36% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.
Mise à jour du récit • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Recent updates
Mise à jour du récit • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.Mise à jour du récit • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Mise à jour du récit • Apr 01
OSUR: Activist Campaign And Governance Changes Will Support Future Upside
Analysts have made a modest adjustment to their price target for OraSure Technologies to $4.00, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiple. What's in the News Altai Capital Management has escalated its campaign, calling for a broad review of options including a potential sale of OraSure Technologies, criticizing executive pay and board oversight, and urging shareholders to support its director nominees Rishi Bajaj and John Bertrand at the 2026 annual meeting (Investor Activism, March 18, 2026).Mise à jour du récit • Mar 18
OSUR: Activist Board Push And Buybacks Will Support Future Upside
Analysts have lifted their price target on OraSure Technologies to $4.00 from $3.00, citing updated expectations regarding revenue growth, profit margins, and a modestly higher future P/E multiple. What's in the News Altai Capital Management sent a letter to OraSure's board on March 17, 2026, outlining a five-pillar case for change, citing share price underperformance, board ownership levels, CEO pay structure, a call for a strategic review, and support for its nominees, Rishi Bajaj and John Bertrand, to join the board (Investor Activism) Altai Capital formally nominated Bajaj and Bertrand for election to the board at the 2026 Annual Meeting and submitted a proposal to declassify the board so all directors stand for annual elections (Investor Activism) OraSure issued first quarter 2026 guidance, projecting total revenues of US$26 million to US$29 million, with only a negligible contribution from COVID 19 testing (Corporate Guidance) The company reported completing a share repurchase of 5,245,180 shares, or 7.12% of its stock, for US$14.89 million under a buyback program announced on March 24, 2025, including 1,900,000 shares bought for US$5 million between October 1 and December 31, 2025 (Buyback Tranche Update) OraQuick HIV Self Test received a Health Canada license as the first oral HIV self test in Canada, offering 20 minute results from an oral swab and distribution through St. Michael's Hospital to support access across healthcare and community settings (Product Related Announcement) Valuation Changes Fair Value: The analyst fair value estimate has risen from $3.00 to $4.00 per share, which represents a material upward revision to the target level.Mise à jour du récit • Mar 04
OSUR: New STI Self Testing Submissions Will Drive Future Upside
Analysts have raised their price target on OraSure Technologies from $4.50 to $5.00, citing updated assumptions around revenue growth, profit margin and future P/E that they state better reflect the company’s current outlook. What's in the News OraSure completed a share repurchase tranche between October 1, 2025 and December 31, 2025, buying 1,900,000 shares, or 2.63% of shares, for US$5 million.Mise à jour du récit • Feb 18
OSUR: New STI Self Testing Submissions Will Support Future Shareholder Upside
Narrative Update on OraSure Technologies Analysts have kept their OraSure Technologies fair value estimate steady at $4.50, with only marginal tweaks to inputs like the discount rate, long term revenue growth, profit margin, and future P/E assumptions driving this maintained price target. What's in the News OraQuick HIV Self-Test received a Health Canada license, becoming Canada's first oral HIV self test and offering results in about 20 minutes from an oral swab for HIV 1 and HIV 2 antibodies.Mise à jour du récit • Feb 04
OSUR: New STI Testing Submissions Will Drive Future Shareholder Value
Analysts have modestly revised their price target for OraSure Technologies to US$4.50, reflecting slightly adjusted assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes leave their overall view of the company’s fair value essentially unchanged.Mise à jour du récit • Jan 21
OSUR: At-Home STI Testing Pipeline Will Drive Future Upside
Analysts have maintained their price target on OraSure Technologies at US$3.00. This reflects updated views on factors such as discount rate, revenue growth assumptions, profit margins, and future P/E expectations, while keeping the headline valuation level unchanged.Mise à jour du récit • Jan 07
OSUR: At-Home STI Testing And Activist Push Will Drive Future Upside
Analysts have kept their fair value estimate for OraSure Technologies steady at US$3.00 per share, citing largely unchanged assumptions around the company’s discount rate, revenue growth outlook, profit margin profile, and future P/E multiple. What's in the News OraSure submitted two applications to the U.S. FDA at the end of 2025 for clearance of a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae and for its Colli-Pee at-home urine collection device for sexually transmitted infections, both aimed at over-the-counter and at-home use (Key Developments).Mise à jour du récit • Dec 23
OSUR: Activist Board Challenge Will Drive Future Shareholder Value Upside
Analysts have reduced their price target on OraSure Technologies from 5.00 dollars to 3.00 dollars per share, citing a higher required return on equity and lower expected future valuation multiples, despite improving revenue growth assumptions and largely stable profit margins. What's in the News Altai Capital Management notified OraSure Technologies Board on December 17, 2025 of its intention to nominate two directors at the 2026 annual meeting, citing share price underperformance and capital allocation concerns (Key Developments).Mise à jour du récit • Dec 09
OSUR: Ongoing Share Repurchases Will Drive Future Shareholder Value
Analysts have raised their price target on OraSure Technologies from 4.50 dollars to 4.75 dollars, citing slightly lower discount rate assumptions and a modestly higher long term valuation multiple, despite a small reduction in projected profit margins. What's in the News Completed a share repurchase of 3,345,180 shares, representing 4.49% of outstanding shares, for a total of $9.89 million under the buyback program announced on March 24, 2025 (Key Developments) From July 1, 2025 to September 30, 2025, repurchased 1,524,424 shares, or 2.07% of outstanding shares, for $4.9 million as the latest tranche of the ongoing buyback (Key Developments) Issued fourth quarter 2025 earnings guidance, projecting total revenues of $25 million to $28 million (Key Developments) Q4 2025 outlook includes less than $100,000 in COVID-19 testing revenue, underscoring the company’s pivot away from pandemic-driven sales (Key Developments) Valuation Changes Fair Value Estimate remains unchanged at 4.50 dollars per share, indicating no revision to the intrinsic value assessment.Mise à jour du récit • Nov 25
OSUR: Share Buybacks And Board Actions Will Drive Shareholder Value
Narrative Update: Analyst Price Target Adjustment for OraSure Technologies Analysts have reduced OraSure Technologies’ price target from $4.75 to $4.50, citing updated assumptions in growth and profitability metrics. What's in the News OraSure Technologies repurchased 1,524,424 shares for $4.9 million during Q3 2025, completing a total buyback of 3,345,180 shares under the repurchase plan announced in March 2025 (Key Developments).Article d’analyse • Nov 14
Revenues Working Against OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Following 25% Dive
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares have had a horrible month, losing 25% after a relatively good period...Mise à jour du récit • Nov 06
OSUR: Activist Pressure Will Drive Shareholder Value Amid Board Challenge
Analysts have revised their price target for OraSure Technologies from $6.00 to $4.75, citing updated projections for revenue growth and broader shifts in valuation estimates. What's in the News Healthcare entrepreneur Ron Zwanziger warned OraSure that he may pursue an adversarial strategy if the company continues to resist his acquisition bid, following OraSure's rejection of his all-cash offer earlier this summer (Reuters).Article d’analyse • Aug 08
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
There's been a notable change in appetite for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares in the week since its...Seeking Alpha • Jul 28
OraSure Technologies: An Asymmetric Bet
Summary OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target. Downside risk is limited by a strong balance sheet and buyback program, while acquisition or Sherlock's success could drive significant upside. Read the full article on Seeking AlphaArticle d’analyse • May 08
Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being
Key Insights OraSure Technologies will host its Annual General Meeting on 14th of May Total pay for CEO Carrie Eglinton...Article d’analyse • Feb 27
Investors Don't See Light At End Of OraSure Technologies, Inc.'s (NASDAQ:OSUR) Tunnel And Push Stock Down 26%
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders won't be pleased to see that the share price has had a very...
Nouveau récit • Feb 09
Launch Of OraQuick HCV Self-Test And Genomics Ventures Will Open Markets Amid Profitability Pressures
The international launch of the OraQuick HCV Self-test and upcoming blood proteomics launch offer significant revenue and growth opportunities.Seeking Alpha • Dec 11
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Summary OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation. Management is competent and aligned with shareholders, enhancing confidence in the company’s ability to capitalize on its undervaluation. Read the full article on Seeking AlphaArticle d’analyse • Nov 14
Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings
Shareholders appeared unconcerned with OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) lackluster earnings report last...Article d’analyse • Nov 08
Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results
OraSure Technologies, Inc. ( NASDAQ:OSUR ) just released its third-quarter report and things are looking bullish...Seeking Alpha • Nov 04
OraSure: An NCAV Diamond In The COVID Rough
Summary OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value. At the same time, OraSure has a stable operational history with consistent normalized cash flow margins. OraSure has the potential to return to its (much higher) historical NCAV multiples, particularly when considering the new management teams' focus on operational efficiency through cost control. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
OraSure Technologies: Nursing A COVID-19 Hangover
Summary Today, we revisit OraSure Technologies, Inc., a diagnostic firm that, like many in the industry, is going through a post-COVID hangover. The good news for the company is it is sitting on a huge cash balance and management is doing a good job of reducing operating expenses. An updated analysis around OraSure Technologies follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • May 11
OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for OraSure Technologies, Inc. ( NASDAQ:OSUR ), who've watched their investment drop 11% to...Article d’analyse • Apr 17
Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
With a price-to-sales (or "P/S") ratio of 1x OraSure Technologies, Inc. ( NASDAQ:OSUR ) may be sending very bullish...Article d’analyse • Mar 01
Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders, because the company has just...Article d’analyse • Feb 29
Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Article d’analyse • Dec 20
OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry
OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) price-to-sales (or "P/S") ratio of 1.3x might make it look like a buy...Rendement pour les actionnaires
| OSUR | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | 20.3% | 4.4% | 1.0% |
| 1Y | 43.3% | -17.9% | 28.7% |
Rendement vs Industrie: OSUR a dépassé le secteur US Medical Equipment qui a rapporté -17.9 % au cours de l'année écoulée.
Rendement vs marché: OSUR a dépassé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| OSUR volatility | |
|---|---|
| OSUR Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: OSUR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de OSUR ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1987 | 500 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc. et ses filiales développent, fabriquent, commercialisent, vendent et distribuent des produits de diagnostic et des dispositifs de prélèvement d'échantillons aux États-Unis, en Europe, en Afrique et dans le monde entier. Elle propose le test rapide OraQuick HIV, l'autotest OraQuick HIV, l'autotest OraQuick HIV (international), le test rapide et l'autotest OraQuick HCV, le test de diagnostic rapide Syphilis health check, le test rapide OraQuick Ebola, le test rapide InteliSwab COVID-19, le test rapide InteliSwab COVID-19 pro, le test rapide InteliSwab COVID-19 rx, le test SickleSCAN et le dispositif OraSure de prélèvement de liquide oral pour les anticorps du VIH-1 ; les systèmes de dépistage de drogues Intercept ; les tests immunologiques et les réactifs ; et le test salivaire Q.E.D., un test d'alcoolémie salivaire. La société fournit également des produits génomiques sous les marques Oragene et ORAcollect pour la collecte de matériel génétique à partir de salive humaine ; des dispositifs de collecte Colli-Pee pour la collecte volumétrique d'échantillons d'urine ; et le dispositif de collecte de sang protéique HEMAcollect.
OraSure Technologies, Inc. Résumé des fondamentaux
| OSUR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$226.51m |
| Bénéfices(TTM) | -US$75.07m |
| Recettes(TTM) | US$113.02m |
2.2x
Ratio P/S-3.3x
Ratio P/ELe site OSUR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| OSUR compte de résultat (TTM) | |
|---|---|
| Recettes | US$113.02m |
| Coût des recettes | US$65.25m |
| Marge brute | US$47.77m |
| Autres dépenses | US$122.84m |
| Les revenus | -US$75.07m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.09 |
| Marge brute | 42.27% |
| Marge bénéficiaire nette | -66.42% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de OSUR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 09:50 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
OraSure Technologies, Inc. est couverte par 15 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |